Evaluation of single-round infectious, chimeric dengue type 1 virus as an antigen for dengue functional antibody assays

Vaccine

Volumn 32, Issue 34, 2014, Pages 4289-4295

  Yamanaka, Atsushi ^a,b   Suzuki, Ryosuke ^c   Konishi, Eiji ^a,b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b OSAKA UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Antibody dependent enhancement; Chimera; Dengue; Neutralizing antibody; Serological test; Viral antigen

Indexed keywords

ANTIGEN; DENGUE VACCINE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; SINGLE ROUND INFECTIOUS PARTICLE; UNCLASSIFIED DRUG; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ANTIGEN;

ARTICLE; BIOTECHNOLOGY; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DRUG SAFETY; EVALUATION STUDY; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOASSAY; JAPANESE ENCEPHALITIS VIRUS; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON; SEROTYPE; VIRUS CAPSID; VIRUS NEUTRALIZATION; VIRUS STRAIN; ADULT; AGED; ANIMAL; CHLOROCEBUS AETHIOPS; CLASSIFICATION; DENGUE VIRUS; HEK293 CELL LINE; IMMUNOLOGY; MIDDLE AGED; PLASMID; PROCEDURES; SERODIAGNOSIS; VERO CELL LINE;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CERCOPITHECUS AETHIOPS; DENGUE VIRUS; HEK293 CELLS; HUMANS; IMMUNOASSAY; MIDDLE AGED; NEUTRALIZATION TESTS; PLASMIDS; REPLICON; VERO CELLS;

EID: 84903819462     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.06.017     Document Type: Article

References (41)

1. Halstead S.B. Dengue. Lancet 2007, 370:1644-1652.
2. Pierson T.C., Diamond M.S. Flaviviruses. Fields virology (sixth edition) 2013, 747-794. Lippincott Williams & Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
3. World Health Organization Fact sheet No.117 Dengue and severe dengue 2013, World Health Organization Fact sheet No. 117, 〈http://www.who.int/mediacentre/factsheets/fs117/en/index.html〉 (accessed 28 February 2014).
4. Messina J.P., Brady O.J., Scott T.W., Zou C., Pigott D.M., Duda K.A., et al. Global spread of dengue virus types: mapping the 70 year history. Trends Microbiol 2014, 22:138-146.
5. Weaver S.C., Vasilakis N. Molecular evolution of dengue viruses: contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral disease. Infect Genet Evol 2009, 9:523-540.
6. Messer W.B., Gubler D.J., Harris E., Sivananthan K., de Silva A.M. Emergence and global spread of a dengue serotype 3, subtype III virus. Emerg Infect Dis 2003, 9:800-809.
7. Bennett S.N., Holmes E.C., Chirivella M., Rodriguez D.M., Beltran M., Vorndam V., et al. Selection-driven evolution of emergent dengue virus. Mol Biol Evol 2000, 20:16501658.
8. Yamanaka A., Mulyatno K.C., Susilowati H., Hendrianto E., Ginting A.P., Sary D.D., et al. Displacement of the predominant dengue virus from type 2 to type 1 with a subsequent genotype shift from IV to I in Surabaya, Indonesia 2008-2010. PLoS One 2011, 6:e27322.
9. Chen S. The origin of dengue viruses caused the DF outbreak in Guangdong province, China, in 2006. Infect Genet Evol 2011, 11:1183-1187.
10. Tissera H.A., Ooi E.E., Gubler D.J., Tan Y., Logendra B., Wahala W.M., et al. New dengue virus type 1 genotype in Colombo, Sri Lanka. Emerg Infect Dis 2011, 17:20532055.
11. Lee K.S., Lo S., Tan S.S., Chua R., Tan L.K., Xu H., et al. Dengue virus surveillance in Singapore reveals high viral diversity through multiple introductions and in situ evolution. Infect Genet Evol 2012, 12:77-85.
12. Normile D. Tropical medicine, Surprising new dengue virus throws a spanner in disease control efforts. Science 2013, 342:415.
13. Wallace D., Canouet V., Garbes P., Wartel T.A. Challenges in the clinical development of a dengue vaccine. Curr Opin Virol 2013, 3:352-356.
14. Ishikawa T., Yamanaka A., Konishi E. A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. Vaccine 2014, 32:1326-1337.
15. Pierson T.C., Diamond M.S. Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med 2008, 10:e12.
16. Morens D.M., Halstead S.B., Marchette N.J. Profiles of antibody-dependent enhancement of dengue virus type 2 infection. Microb Pathog 1987, 3:231-237.
17. Huisman W., Martina B.E., Rimmelzwaan G.F., Gruters R.A., Osterhaus A.D. Vaccine-induced enhancement of viral infections. Vaccine 2009, 27:505-512.
18. Heinz F.X., Stiasny K. Flaviviruses and flavivirus vaccines. Vaccine 2012, 30:43014306.
19. Halstead S.B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003, 60:421-467.
20. Ministry of Economy, Trade and Industry of Japan Security Export Control System in Japan 2009, http://www.meti.go.jp/policy/anpo/englishpage/overview.pdf.
21. United Nations Nagoya Protocol on access to genetic resources and the fair and equitable sharing of benefits arising from their utilization to the Convention on Biological Diversity 2011, http://www.cbd.int/abs/doc/protocol/nagoya-protocol-en.pdf.
22. Kapoor M., Zhang L., Mohan P.M., Padmanabhan R. Synthesis and characterization of an infectious dengue virus type-2 RNA genome (New Guinea C strain). Gene 1995, 162:175-180.
23. Kinney R.M., Butrapet S., Chang G.J., Tsuchiya K.R., Roehrig J.T., Bhamarapravati N., et al. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 1997, 230:300-308.
24. Puri B., Polo S., Hayes C.G., Falgout B. Construction of a full length infectious clone for dengue-1 virus Western Pacific,74 strain. Virus Genes 2000, 20:57-63.
25. Pierro D.J., Salazar M.I., Beaty B.J., Olson K.E. Infectious clone construction of dengue virus type 2, strain Jamaican 1409, and characterization of a conditional E6 mutation. J Gen Virol 2006, 87:2263-2268.
26. Suzuki R., Ishikawa T., Konishi E., Matsuda M., Watashi K., Aizaki H., et al. Production of single-round infectious chimeric flaviviruses with DNA-based Japanese encephalitis virus replicon. J Gen Virol 2014, 95:60-65.
27. Yamanaka A., Kosugi S., Konishi E. Infection-enhancing and -neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels. J Virol 2008, 82:927-937.
28. Konishi E., Kosugi S., Imoto J. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 2006, 24:2200-2207.
29. Konishi E., Sakai Y., Kitai Y., Yamanaka A. Prevalence of antibodies to Japanese encephalitis virus among inhabitants in Java Island, Indonesia, with a small pig population. Am J Trop Med Hyg 2009, 80:856-861.
30. Yamanaka A., Kotaki T., Konishi E. A mouse monoclonal antibody against dengue virus type 1 Mochizuki strain targeting envelope protein domain II and displaying strongly neutralizing but not enhancing activity. J Virol 2013, 87:12828-12837.
31. Konishi E., Yagawa K., Yamanaka A. Vero cells infected with vaccinia viruses expressing Japanese encephalitis virus envelope protein induce polykaryocyte formation under neutral conditions. Jpn J Infect Dis 2008, 61:410-411.
32. Konishi E., Shoda M., Ajiro N., Kondo T. Development and evaluation of an enzyme-linked immunosorbent assay for quantifying antibodies to Japanese encephalitis virus nonstructural 1 protein to detect subclinical infections in vaccinated horses. J Clin Microbiol 2004, 42:5087-5093.
33. Konishi E., Tabuchi Y., Yamanaka A. A simple assay system for infection-enhancing and -neutralizing antibodies to dengue type 2 virus using layers of semi-adherent K562 cells. J Virol Methods 2010, 163:360-367.
34. Sabchareon A., Wallace D., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 380:1559-1567.
35. McArthur M.A., Sztein M.B., Edelman R. Dengue vaccines: recent developments, ongoing challenges and current candidates. Expert Rev Vaccines 2013, 12:933-953.
36. Rodrigo W.W., Alcena D.C., Rose R.C., Jin X., Schlesinger J.J. An automated Dengue virus microneutralization plaque assay performed in human Fc{gamma} receptor-expressing CV-1 cells. Am J Trop Med Hyg 2009, 80:61-65.
37. Moi M.L., Lim C.K., Chua K.B., Takasaki T., Kurane I. Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using FcgammaR-expressing cells. PLoS Negl Trop Dis 2012, 6:e1536.
38. Mason P.W., Pincus S., Fournier M.J., Mason T.L., Shope R.E., Paoletti E. Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology 1991, 180:294-305.
39. Konishi E., Pincus S., Fonseca B.A., Shope R.E., Paoletti E., Mason P.W. Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus. Virology 1991, 185:401-410.
40. Konishi E., Mason P.W., Shope R.E. Enzyme-linked immunosorbent assay using recombinant antigens for serodiagnosis of Japanese encephalitis. J Med Virol 1996, 48:76-79.
41. Chiou S.S., Crill W.D., Chen L.K., Chang G.J. Enzyme-linked immunosorbent assays using novel Japanese encephalitis virus antigen improve the accuracy of clinical diagnosis of flavivirus infections. Clin Vaccine Immunol 2008, 15:825-835.